Search Result

Results for "

ISGs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HBV (1) HCV (1) IFNAR (2) JAK (3) Lactate Dehydrogenase (1) NF-κB (1) Small Interfering RNA (siRNA) (2) STAT (2) STING (9)
By Research Areas:	Cancer (6) Infection (8) Inflammation/Immunology (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

RIG012	IFNAR	Infection Cancer
RIG012 is a potent RIG-I inhibitor with an IC₅₀ of 0.71 μM using the NADH-coupled ATPase assay. RIG012 inhibits IFN-β and ISG hRsad2 expression .

RO8191 5+ Cited Publications CDM-3008; RO4948191	IFNAR JAK STAT HCV HBV	Infection
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC₅₀ of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .

SR-717 Maximum Cited Publications 10 Publications Verification	STING	Inflammation/Immunology Cancer
SR-717 is a non-nucleotide STING agonist with EC₅₀s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .

ISG15 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ISG15 Human Pre-designed siRNA Set A contains three designed siRNAs for ISG15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ISG15 Human Pre-designed siRNA Set A ISG15 Human Pre-designed siRNA Set A

ISG20 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ISG20 Human Pre-designed siRNA Set A contains three designed siRNAs for ISG20 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ISG20 Human Pre-designed siRNA Set A ISG20 Human Pre-designed siRNA Set A

SR-717 free acid	STING	Inflammation/Immunology Cancer
SR-717 free acid is a non-nucleotide STING agonist with EC₅₀s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 free acid is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity .

STING agonist-23	STING	Infection
STING agonist-23 (CF502) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, *ISG-15, and CCL-5* in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

STING agonist-24	STING	Infection
STING agonist-24 (CF504) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, *ISG-15, and CCL-5* in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

STING agonist-25	STING	Infection
STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, *ISG-15, and CCL-5* in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

STING agonist-26	STING	Infection
STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, *ISG-15, and CCL-5* in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

STING agonist-28	STING	Infection
STING agonist-28 (CF510) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, *ISG-15, and CCL-5* in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains .

ChX710 2 Publications Verification	STING	Cancer
ChX710 could prime the type I interferon response to cytosolic DNA, which induces the ISRE promoter sequence, specific cellular Interferon-Stimulated Genes (ISGs), and the phosphorylation of Interferon Regulatory Factor (IRF) 3.

Ruxolitinib (S enantiomer) 4 Publications Verification S-Ruxolitinib; S-INCB18424	JAK	Cancer
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor .

MEDS433	Lactate Dehydrogenase	Infection
MEDS433 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC₅₀ of 1.2 nM. MEDS433 exerts a potent antiviral activity against RSV-A and RSV-B in the one-digit nanomolar range. MEDS433 induces the expression of antiviral proteins encoded by interferon stimulated genes (ISGs) able to reduce RSV replication .

Z36-MP5	Others	Cancer
Z36-MP5 is an Mi-2β-targeted inhibitor, with IC₅₀ of 0.082 μM. Z36-MP5 can reduce Mi-2β ATPase activity and reactivates ISG transcription. Z36-MP5 can stimulate T-cell-mediated cytotoxicity .

JAK-IN-23	JAK STING NF-κB STAT	Inflammation/Immunology
JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC₅₀ values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC₅₀ values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Name
Email *

	Sorry, but the email address you supplied was invalid.

Inhibitors & Agonists